Prospective Study for the Outpatient Treatment of Patients With Very Low Risk Acute Symptomatic Pulmonary Embolism.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-10

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives: To evaluate the safety of outpatient treatment of patients with very low-risk pulmonary embolism (PE), and the satisfaction and quality of life of this management.

Methods: An experimental study of routine clinical practice will be carried out in which 300 consecutive hemodynamically stable patients with acute symptomatic PE will be included, who meet all the inclusion criteria and none of the exclusion criteria. All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department. The Computerized Registry of Thromboembolic Disease RIETE (Registro Informatizado de Enfermedad TromboEmbólica) will be used to collect the data in electronic case report form (CRF) and ensure the quality of the data.

Setting: Emergency, Pneumology and Internal Medicine Services of 10 Spanish hospitals.

Analysis: An intention-to-treat (ITT) analysis will be performed on all patients who sign the informed consent and are included in the study (regardless of whether or not they receive the assigned strategy). Additionally, an analysis of all patients who are treated on an outpatient basis without deviations or violations of the protocol will be performed. The primary outcome considered will be the composite of recurrent PE, major bleeding, or death from any cause during the first 30 days after enrollment in the study. Patient satisfaction and quality of life will be considered as secondary outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Epidemiology of Thromboembolism Disease: A Cohort Study

NCT00670540

Vascular Diseases Embolism and Thrombosis Phlebitis +2 more

COMPLETED

Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant

NCT02079584

Venous Thromboembolism

COMPLETED

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569

Pulmonary Embolism

RECRUITING PHASE3

Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events

NCT02155491

Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism

COMPLETED

Tinzaparin in the Treatment of the Acute Pulmonary Embolism

NCT00711308

Acute Pulmonary Embolism

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Pulmonary Embolism Outpatient Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemodynamically stable patients with very low risk symptomatic acute pulmonary embolism (PE)

Group Type EXPERIMENTAL

Outpatient treatment with standard anticoagulant therapy

Intervention Type OTHER

All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Outpatient treatment with standard anticoagulant therapy

All patients included in the study will be treated on an outpatient basis, that is, they will be discharged within the first 24 hours of the diagnosis of PE in the Emergency Department.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmation of suspected pulmonary embolism (PE) by multidetector chest angio computed tomography (CT), if a contrast-encircled partial intraluminal defect or complete pulmonary artery occlusion is demonstrated on two consecutive CT slices (13);
* Right ventricle (RV) diameter equal to or less than that of the left ventricle (LV) (RV/LV ratio ≤1) on chest CT angiography (see Study Procedures); and
* Negatively modified simplified Pulmonary Embolism Severity Index (sPESI) scale at the time of evaluation of the patient in the Emergency Department.

Exclusion Criteria

* Inability to obtain informed consent
* Pregnancy
* Hemodynamic instability at diagnosis (defined by systolic blood pressure (SBP) \<90 mm Hg, indication of fibrinolytic treatment or inferior vena cava filter, need for vasoactive drugs at the discretion of the attending physician, cardiopulmonary resuscitation or orotracheal intubation)
* Contraindication for anticoagulation, at the discretion of the responsible physician;
* Estimated survival of less than 3 months
* Need for thrombectomy, vena cava filter insertion, or need for fibrinolytic treatment of the PE episode at the time of diagnosis
* Participation in a clinical trial for the treatment of venous thromboembolic disease
* Impossibility of follow up

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

PEDRO Ruiz-Artacho, PhD, MD

Role: STUDY_DIRECTOR

Clínica Universidad de Navarra, Madrid (España)

Raquel Morillo Guerrero, PhD, MD

Role: STUDY_DIRECTOR

Hospital Ramón y Cajal, Madrid (España)

DAVID Jiménez Castro, PhD, MD

Role: STUDY_DIRECTOR

Hospital Ramón y Cajal, Madrid (España)

Deisy Barrios Barreto, PhD, MD

Role: STUDY_DIRECTOR

Hospital Ramón y Cajal, Madrid (España)

Pablo Demelo Rodríguez, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Gregorio Marañón, Madrid (España)

Alberto García-Ortega, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Doctor Peset, Valencia (España)

Andrea Pérez Figuera, MD

Role: STUDY_DIRECTOR

Hospital Ramón y Cajal, Madrid (España)

Elena Hernando López, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital San Pedro, Logroño (España)

Luis Jara Palomares, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Complejo Hospitalario Virgen del Rocío, Sevilla (España)

Jorge Moisés Lafuente, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Clinic (España)

Ignacio Casado Moreno, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Virgen de las Nieves, Granada (España

Tina Rivas, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Donostia (España)

Daniel Segura Ayala, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital General Universitari de Castelló (España)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.